Personalis, Inc. (PSNL)

NGM – Цена в реальном времени. Валюта: USD

13.02

+0.43 (3.42%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

12.90

-0.12 (-0.92%)

После закрытия: Jun 26, 2026, 7:44 PM EDT

09.06.2026

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union's In Vitro Diagnostic Regulation (IVDR). The CE Mark represents an important regulatory milestone, ensuring that clinical trial sites throughout the European Union and Great Britain can use these col.

02.06.2026

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with NeXT Per.

28.05.2026

Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating

Personalis, Inc. is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions. Despite a projected 2026 net loss of ~$100m and 14% revenue growth, PSNL's clinical test volume is ramping rapidly, with 43k–45k tests targeted this year. Key catalysts include expanded CMS MolDX coverage for breast and lung cancer recurrence monitoring and potential M&A interest given an $887m market cap.

20.05.2026

US Agency Broadens Coverage Of Personalis Breast Cancer Test

Personalis Inc. (NASDAQ:PSNL) received a favorable reimbursement decision that could make its cancer test available to more patients — and more likely to be paid for by Medicare.

20.05.2026

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company's NeXT Personal minimal residual disease (MRD) test. The new coverage determination is for monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III Triple-Negative Breast Canc.

14.05.2026

Personalis to Participate in Upcoming Investor Events

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the following investor events: Craig Hallum 23rd Annual Institutional Investor Conference on May 28, 2026 at the Depot Renaissance Hotel in Minneapolis, MN. Jefferies 2026 Global Healthcare Conference on June 3, 2026 at the Marriot Marquis in New York, NY. About Personalis, Inc. At Personalis, we are transformi.

13.05.2026

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company's NeXT Personal minimal residual disease (MRD) test to include immunotherapy monitoring for patients with late-stage solid tumors. This coverage determination is underpinned by landmark clinical evidence generated in.

Видео

No Data

There is no data to display

Пресс-релизы

09.06.2026

Personalis, Inc. (PSNL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Personalis, Inc. (PSNL)

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating

US Agency Broadens Coverage Of Personalis Breast Cancer Test

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

Personalis to Participate in Upcoming Investor Events

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

Видео

No Data

Пресс-релизы

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating

US Agency Broadens Coverage Of Personalis Breast Cancer Test

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

Personalis to Participate in Upcoming Investor Events

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

Видео

No Data

Пресс-релизы

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

Personalis to Participate in Upcoming Investor Events

Search stocks

Personalis, Inc. (PSNL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Personalis, Inc. (PSNL)

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating

US Agency Broadens Coverage Of Personalis Breast Cancer Test

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

Personalis to Participate in Upcoming Investor Events

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

Видео

No Data

Пресс-релизы

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating

US Agency Broadens Coverage Of Personalis Breast Cancer Test

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

Personalis to Participate in Upcoming Investor Events

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

Видео

No Data

Пресс-релизы

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

Personalis to Participate in Upcoming Investor Events